Stopping Is Not Neutral: Why Withdrawing Hormone Therapy Asks the Same Rigour as Starting It — Anatomy of Good Care (1/7)

The question we forget to ask

When a patient starts hormone therapy, we are thorough. We take a history, run baselines, talk through risks and benefits, document consent, and set a monitoring schedule. We treat initiation as what it is — a clinical decision with consequences that deserves care.

When the same therapy stops, that scrutiny often evaporates. A prescription lapses, a service is disrupted, a supply runs out, and the stopping passes without anything like the examination we gave the starting. The unspoken assumption is that withdrawal is simply the undoing of a treatment — a step back to a neutral baseline.

For a patient established on estradiol or testosterone, there is often no neutral baseline to step back to — and after gonadectomy, none at all. Starting and stopping are both interventions. We just only treat one of them that way.

What the body does when estradiol is withdrawn

The most familiar consequence of estrogen withdrawal is vasomotor: hot flushes and night sweats. The leading mechanistic account locates this in the hypothalamus, where a population of neurons (the KNDy neurons) helps regulate the body’s thermoneutral zone. Estrogen normally restrains them; when estrogen falls, they are disinhibited and the thermoneutral zone narrows, so ordinary shifts in temperature start triggering a flush response [1]. Notably, the better evidence suggests it is the downward swing in estradiol, rather than a low level in itself, that precipitates symptoms — which is precisely why withdrawal, the act of stopping, is the trigger [2]. (Mechanism characterised chiefly in cis menopausal cohorts and the animal/neuroendocrine literature; used here as the prevailing model for estrogen-withdrawal physiology, not as trans-specific outcome evidence.)

This is not uniform. Some people withdraw from estrogen with little vasomotor disturbance — in one controlled study, postmenopausal women with no prior history of flushes did not reliably develop them after abruptly stopping short-term estradiol [3]. Individual response varies, and we should say so. The point is not that withdrawal always produces a crisis; it is that withdrawal predictably does something, and that something is unpredictable enough to warrant attention rather than assumption.

The higher-stakes consequence is skeletal, and here the asymmetry is starkest. Estrogen is a brake on bone resorption. The loss of estrogen at menopause increases osteoclast activity and lowers bone mineral density [4]. (General/cis bone physiology.) And when menopausal hormone therapy is discontinued, bone loss can be clinically meaningful and relatively rapid — concentrated in the first two years, on the order of 1.5–2% per year, mirroring the loss seen in early menopause itself [5]. (Again, cis menopausal women — but the physiology of estrogen withdrawal on bone is the relevant read-across.)

For a trans woman who has had an orchidectomy, this stops being an analogy. After gonadectomy there is no endogenous gonadal estrogen to fall back on. Exogenous estradiol is the supply. Stopping it does not return her to some prior hormonal state — it leaves her in an unprotected, low-sex-steroid state. This is why specialist guidance names underutilisation of hormones after gonadectomy as a recognised osteoporosis risk factor, and recommends bone-density assessment for anyone who has had a gonadectomy and five or more years without hormone replacement, regardless of age [6]. It is borne out in the cohort data: trans women after gender-confirming surgery show a high prevalence of low bone mass, statistically tied to low estradiol levels and poor adherence to replacement [7], and fracture risk in older trans women has been reported as higher than in age-matched reference men even among those recorded as using long-term hormone therapy [8] — which suggests that hormone therapy may mitigate, but does not necessarily erase, baseline skeletal vulnerability. It is therefore not safe to assume that withdrawal would be benign.

The same principle applies to testosterone

The same logic runs through testosterone, and it is sometimes missed because we picture testosterone as the “active” hormone and forget what it is protecting against. A trans man who has had bilateral oophorectomy has no ovarian source of sex steroids; in transmasculine people on testosterone, oophorectomy has been associated with significantly lower serum estradiol than pre-surgical levels [9]. The working clinical assumption is that he will continue testosterone indefinitely — and continuation is what guards against the long-term morbidity of an early surgical menopause. That assumption does not always hold: case series document real-world interruptions of testosterone after oophorectomy, and the counselling and planning they call for [10]. Gonadectomy leaves an iatrogenic hypogonadal state that can harm bone unless gender-affirming hormones are consistently continued [11]; consistent with this, longitudinal data show measurable falls in bone-density Z-scores in the bilateral-oophorectomy subgroup — supporting ongoing monitoring and adequate replacement rather than a presumption of harm in every case [12]. Specialist guidance lists oophorectomy before age 45 without optimal hormone replacement as a recognised osteoporosis risk factor [6].

So the principle holds across both directions of care: after gonadectomy, hormone therapy is not an enhancement layered on top of a self-sustaining gonadal system. For practical clinical purposes, it is the main source of sex-steroid support. Stopping it is a withdrawal of physiological support, with a predictable direction of harm.

A caveat that sharpens the point rather than softening it: before gonadectomy the picture is more variable. A trans woman who stops estradiol and stops her anti-androgen will usually see endogenous testosterone production resume, which lends the skeleton some protection; the same holds in reverse for a trans man with intact ovaries. But if estradiol lapses while androgen suppression continues — for example, when one prescription is interrupted but the other continues — the patient may be left in a very low-sex-steroid state despite having gonads. The post-gonadectomy case is simply the version where that state is guaranteed rather than possible.

The wellbeing question, answered honestly

It would be easy, and rhetorically tempting, to claim that stopping hormones reliably harms mental health. The evidence doesn’t license a claim that strong, and overstating it would be its own kind of error. What the literature reasonably supports is that starting gender-affirming hormone therapy is associated with improvements in depression and anxiety for many adults [13] — and one randomised comparison found reductions in depressive symptoms within three months of initiation relative to delayed access [14] — though the picture is not perfectly uniform across cohorts.

The direct, high-quality evidence on the psychological effects of withdrawing established gender-affirming hormone therapy is limited. That limitation should make clinicians more careful, not less. We do not have evidence that abruptly stopping established hormone therapy is psychologically neutral; in the absence of that evidence, treating withdrawal as a non-event is not a cautious position — it is an unexamined one. The burden of proof sits with the act that changes the status quo, and stopping is that act.

What stopping properly actually looks like

Here is the quiet tell in all of this. When clinicians write about how to come off sex-hormone therapy, they do not describe a non-event — they describe something to be anticipated, planned, and monitored. Symptom recurrence after stopping is common; and while trials have not actually established that a gradual taper outperforms abrupt cessation, that is rather the point — stopping is a clinical event that has to be managed however it is done, not a default that manages itself [15]. For short-acting oral estrogen regimens, intermittent missed doses produce fluctuating exposure rather than a smooth reduction; a planned dose reduction or formulation change is a different thing from an unmanaged lapse.

In other words, the considered way to stop is itself an active clinical process — assessed, planned, monitored, supported. Which is the whole argument in miniature: if stopping safely requires all of that, then stopping is not a neutral default. An abrupt, unmanaged cessation isn’t the absence of an intervention. It is the unmanaged version of one.

The principle

In a patient who is stable on treatment, and absent a patient-led decision to stop or a specific clinical contraindication, continuation is the clinically safer default. Withdrawal is the deviation, and when it is unplanned or clinician-driven it requires its own justification and its own evidence — held to the same standard we would demand before we ever began.

This is not an argument against stopping when the patient wants to stop, or when a specific medical reason makes stopping necessary. It is an argument against treating interruption, refusal, or unmanaged withdrawal as clinically neutral.

A patient stable on treatment is owed the same rigour on the way out as on the way in. Anything less — when withdrawal is imposed by a clinician, a system, or a lapse in access rather than chosen by the patient — is not caution. It is a second intervention, performed without the same consent and clinical care we required at initiation.

Sources

1. Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives. International Journal of Women’s Health, 2023. — Hypothalamic KNDy-neuron mechanism and thermoneutral-zone narrowing on estrogen withdrawal. (Population: cis menopausal women.)
2. Paradigm shift in the pathophysiology of vasomotor symptoms: effects of estradiol withdrawal and progesterone therapy. ScienceDirect, 2020. — Evidence that the downward swing in estradiol, not low estradiol alone, drives vasomotor symptoms. (Population: peri/menopausal women; presented as a model.)
3. Hammar M, et al. Postmenopausal women without previous or current vasomotor symptoms do not flush after abruptly abandoning estrogen replacement therapy. Maturitas, 1999;31(2):117–122. PMID 10227004. — Individual variation; abrupt withdrawal did not reliably induce flushes in women with no prior history. (Population: postmenopausal women.)
4. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends in Endocrinology and Metabolism, 2012. PMCID PMC3424385. — Estrogen is the principal restraint on bone resorption; its loss increases osteoclast activity and lifespan and lowers bone mineral density. (Population: general/cis bone physiology; women and men.)
5. Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review. Hormones (Athens), 2024. PMC11219436. — On MHT discontinuation, rapid bone loss occurs mostly within the first ~2 years, ~1.5–2%/yr, identical to that of early menopause. (Population: cis menopausal women.)
6. Bone health and osteoporosis. UCSF Gender Affirming Health Program — Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. — Hormone underutilisation after gonadectomy as a recognised osteoporosis risk; DXA recommended after gonadectomy with ≥5 years without replacement, regardless of age; oophorectomy before age 45 without optimal replacement listed as a risk factor. (Trans-specific.)
7. Motta G, et al. Fracture risk assessment in an Italian group of transgender women after gender-confirming surgery. Journal of Bone and Mineral Metabolism (Turin cohort), 2020;38(6):885–893. PMID 32691168. — High prevalence of low bone mass (Z-score ≤ −2 in 40%), significantly linked to low estradiol and low adherence to estrogen replacement. (Trans-specific.)
8. Wiepjes CM, et al. Fracture Risk in Trans Women and Trans Men Using Long-Term Gender-Affirming Hormonal Treatment: A Nationwide Cohort Study. Journal of Bone and Mineral Research, 2020;35(1):64–70. — In trans women ≥50 on long-term hormone therapy, fracture prevalence 4.4% vs 2.4% in age-matched reference men (OR 1.90, 95% CI 1.32–2.74). Used here for the reported fracture comparison only; the mitigation/withdrawal reading is presented as inference, not a demonstrated finding. (Trans-specific.)
9. Serum estradiol levels decrease after oophorectomy in transmasculine individuals on testosterone therapy. Asian Journal of Andrology, 2022. PMID 36124534; DOI 10.4103/aja202262. Retrospective chart review, Vancouver, BC (12 cases vs 12 matched controls). — Serum estradiol fell significantly below pre-surgical levels after oophorectomy (P = 0.02). (Trans-specific.)
10. Barrera EP, Grimstad FW, Boskey ER. Young Adult Patients with Testosterone Management Concerns after Gender-Affirming Hysterectomy and Bilateral Oophorectomy: A Case Series. Journal of Pediatric and Adolescent Gynecology, 2023;36(1):89–91 (epub 2022). DOI 10.1016/j.jpag.2022.07.010; PMID 35850361. — Case series (n=3) documenting that real-world testosterone interruptions occur after oophorectomy and that counselling/planning are needed. Used for proof-of-occurrence, not population-level morbidity. (Trans-specific.)
11. Giacomelli G, Meriggiola MC. Bone health in transgender people: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 2022. DOI 10.1177/20420188221099346. — Surgical removal of the gonads produces an iatrogenic hypogonadal state that can negatively affect bone homeostasis if gender-affirming hormone therapy is not consistently continued. (Trans-specific.)
12. Sanna E, et al. Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy. Frontiers in Endocrinology (Lausanne), 2024;15:1416121. PMID 39391880. — Longitudinal DXA: the bilateral-oophorectomy subgroup showed significant Z-score reductions at lumbar spine, femoral neck and total hip at 5 years (and lumbar spine at 10 years), alongside lower estradiol — supporting monitoring and adequate replacement. (Trans-specific.)
13. Aldridge Z, Patel S, Guo B, Nixon E, Pierre Bouman W, Witcomb GL, Arcelus J. Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study. Andrology, 2021;9(6):1808–1816. DOI 10.1111/andr.12884; PMID 32777129. — 18-month prospective cohort (n=178); initiation associated with mental-health improvement for many adults; heterogeneity acknowledged. (Trans-specific.)
14. Nolan BJ, Zwickl S, Locke P, Zajac JD, Cheung AS. Early access to testosterone therapy in transgender and gender-diverse adults seeking masculinization: a randomized clinical trial. JAMA Network Open, 2023;6(9):e2331919. DOI 10.1001/jamanetworkopen.2023.31919; PMID 37676662. — Three-month open-label RCT (n=64), immediate vs delayed testosterone; clinically significant reduction in depressive symptoms (PHQ-9) and in suicidality relative to delayed access. Addresses initiation, not withdrawal. (Trans-specific.)
15. Menopause: diagnosis and management — evidence review on starting and stopping HRT. National Institute for Health and Care Excellence (NICE). NCBI Bookshelf NBK343480. — Discontinuation treated as a planned clinical decision with anticipated symptom recurrence; four RCTs comparing tapered vs abrupt cessation found tapering did not reliably prevent symptom recurrence (taper-vs-abrupt superiority not established). (Population: cis menopausal women.)